Oxford-ZEISS advances breakthrough live-cell imaging platform for next-gen drug discovery
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
The 12-month alpha-testing phase will bring together ZEISS R&D, three academic collaborators, and three pharmaceutical industry partners
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Novel illumination system with key components molded in Radel® PPSU for durability and repeated sterilization
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
The newly launched Genomic Health Insights (GHI) program to make sequencing accessible to all
Subscribe To Our Newsletter & Stay Updated